VanEck Biotech ETF Rating $158.18 -0.27 (-0.17%) As of 01/17/2025 03:58 PM Eastern Add Compare Share Share Ratings Stock AnalysisChartDividendHoldingsOptions ChainOwnershipRatingsShort InterestTrends VanEck Biotech ETF Aggregate Rating and Price Target (2025)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.BBH Aggregate RatingModerate Buy 2.65Holdings in BBH have an aggregate rating of Moderate Buy based on 486 analyst ratings issued in the past year covering 25 companies (100.0% of the portfolio).BBH Aggregate Price Target$158.18High Prediction$158.18Average Prediction$158.18Low Prediction$158.18Holdings in BBH have an aggregate price target of $158.18 and a range of $158.18 to $158.18 covering 25 companies (100.0% of the portfolio).BBH Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy2 Buy rating(s)Moderate Buy18 Moderate Buy rating(s)Hold4 Hold rating(s)Reduce1 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by VanEck Biotech ETF Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 25 BBH Holdings Export to ExcelWeight In ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings15.46%AMGNAmgen$272.11+1.0%4.8924 of 5 stars2.44$314.91 15.7%27News CoveragePositive NewsGap Up11.84%GILDGilead Sciences$91.84+0.2%4.3857 of 5 stars2.70$97.96 6.7%27Insider TradeShort Interest ↑Analyst RevisionNews Coverage10.49%VRTXVertex Pharmaceuticals$422.00+1.2%4.1807 of 5 stars2.52$490.38 16.2%316.57%REGNRegeneron Pharmaceuticals$681.58-1.7%4.6614 of 5 stars2.65$1,015.38 49.0%23Analyst ForecastNews Coverage5.41%ARGXargenx$640.52-2.9%2.2872 of 5 stars2.86$658.39 2.8%22Analyst ForecastAnalyst RevisionNews Coverage4.65%IQVIQVIA$197.25-0.2%4.9021 of 5 stars2.90$255.82 29.7%21Short Interest ↑News Coverage4.44%NTRANatera$158.36-6.0%2.1855 of 5 stars3.00$160.63 1.4%16Analyst ForecastNews CoverageGap UpHigh Trading Volume4.14%ILMNIllumina$136.67-0.5%4.6421 of 5 stars2.70$165.63 21.2%20Short Interest ↓News Coverage3.83%ALNYAlnylam Pharmaceuticals$246.27-1.2%4.3797 of 5 stars2.72$298.61 21.3%25Analyst RevisionNews Coverage3.68%ICLRICON Public$198.11-2.2%4.3182 of 5 stars2.87$287.00 44.9%15Analyst ForecastAnalyst Revision3.32%BIIBBiogen$140.55-0.5%4.7146 of 5 stars2.43$230.00 63.6%28Short Interest ↑2.66%NBIXNeurocrine Biosciences$143.26+0.9%4.8842 of 5 stars2.83$164.81 15.0%23Insider TradeNews Coverage2.58%BNTXBioNTech$111.93-0.7%2.6873 of 5 stars2.88$142.72 27.5%17Short Interest ↑Gap Down2.52%MRNAModerna$34.06+0.9%4.7373 of 5 stars2.13$75.58 121.9%23Analyst ForecastOptions VolumeAnalyst RevisionNews Coverage2.31%SRPTSarepta Therapeutics$118.00+0.8%4.9454 of 5 stars2.91$178.71 51.5%22Analyst ForecastAnalyst RevisionNews Coverage2.11%TECHBio-Techne$75.83-0.4%3.8681 of 5 stars2.63$82.00 8.1%82.11%INSMInsmed$72.51-0.3%2.7837 of 5 stars3.00$83.67 15.4%16Insider TradeShort Interest ↑News Coverage1.88%QGENQiagen$46.00+0.2%4.0945 of 5 stars2.56$51.50 12.0%9Short Interest ↓News Coverage1.82%CRLCharles River Laboratories International$163.77-1.2%4.8386 of 5 stars1.94$209.00 27.6%16Analyst ForecastShort Interest ↑Analyst RevisionNews CoverageHigh Trading Volume1.76%BGNEBeiGene2.4 of 5 stars2.75$253.69 0.0%8Positive News1.61%INCYIncyte$71.93-0.7%4.7449 of 5 stars2.35$76.29 6.1%20Analyst ForecastShort Interest ↓News Coverage1.43%EXASExact Sciences$51.74+2.6%4.764 of 5 stars2.94$72.94 41.0%18News CoverageGap UpHigh Trading Volume1.41%BMRNBioMarin Pharmaceutical$61.53+0.5%4.9993 of 5 stars2.74$94.20 53.1%23Options VolumeNews Coverage1.30%RGENRepligen$160.51-1.4%3.7388 of 5 stars2.62$185.20 15.4%130.66%CYTKCytokinetics$45.74-2.7%4.3227 of 5 stars2.80$83.64 82.9%15Analyst Forecast This page (NASDAQ:BBH) was last updated on 1/18/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredStunning Trump Exec Order LeakedMost people have no clue this unassuming facility exists. Yet the minute Donald Trump takes office... ...Banyan Hill Publishing | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredInvesting Tools You’ll Need for 2025Investing Tools You’ll Need for 2025 Charles Payne Shares His #1 Strategy for 2025 Unstoppable Prosperity | SponsoredBitcoin to $200K?Newsweek recently asked several analysts whether they think Bitcoin will hit $200,000 by the end of 2025. T...Stansberry Research | SponsoredElon's "Final Move" Could Send This Stock SoaringWhenever Elon Musk starts a new venture... Early investors get the opportunity to become millionaires... ...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding VanEck Biotech ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share VanEck Biotech ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
